Table 3.

Drugs approved in United States for treating osteoporosis

Drug	Drug class	Dose, route of administration and dosing interval	Approved for treating men with osteoporosis	Fracture risk reduction (in primary analyses of registration trials)			Subgroup analysis of older study participants
				Vertebral fracture	Nonvertebral fracture	Hip fracture
Raloxifene	EAA	60 mg po daily		✓
Alendronate	bisphosphonate	70 mg po once weekly	✓	✓		✓	✓
Risedronate	bisphosphonate	35 mg po once weekly or 150 mg po once monthly	✓	✓	✓	✓	✓
Ibandronate	bisphosphonate	150 mg po once monthly or 3 mg IV every 3 months		✓
Zoledronate	bisphosphonate	5 mg IV every year	✓	✓	✓	✓	✓
Denosumab	RANK ligand inhibitor	60 mg SQ once every 6 months	✓	✓	✓	✓	✓
Teriparatide	PTH receptor agonist	20 mcg SQ daily	✓	✓	✓		✓
Abaloparatide	PTH receptor agonist	80 mcg SQ daily		✓	✓		✓
Romosozumab	sclerostin inhibitor	210 mg SQ once monthly		✓	✓	✓
Calcitonin-salmon	calcitonin	200 USP units by nasal spray daily		✓

Abbreviations: EAA, estrogen agonist/antagonist; IV, intravenous; PTH, parathyroid hormone; SQ, subcutaneous.